# A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

Study · id `cardio:ct-nct05628311` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05628311](<https://clinicaltrials.gov/study/NCT05628311>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05628311

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.

## Technical summary

Registry record NCT05628311. Randomized; double masking; primary purpose treatment. Start 2023-01-06 (actual); primary completion 2023-10-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 319 participants (enrolled count; ClinicalTrials.gov record NCT05628311, source copy `cardio:ctgov-nct05628311-2024-08-20`, retrieved 2026-10-26)
- Started: 2023-01-06 (actual) (ClinicalTrials.gov record NCT05628311, source copy `cardio:ctgov-nct05628311-2024-08-20`, retrieved 2026-10-26)
- Primary completion: 2023-10-25 (actual) (ClinicalTrials.gov record NCT05628311, source copy `cardio:ctgov-nct05628311-2024-08-20`, retrieved 2026-10-26)
- Completion: 2024-05-09 (actual) (ClinicalTrials.gov record NCT05628311, source copy `cardio:ctgov-nct05628311-2024-08-20`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05628311, source copy `cardio:ctgov-nct05628311-2024-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05628311-2024-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
- Condition: Type 2 Diabetes
- Intervention (Other): placebo
- Intervention (Drug): IBI362
- Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Innovent Biologics (Suzhou) Co. Ltd. (`cardio:org-innovent-biologics-suzhou-co-ltd`)

## Provenance

Content hash: e008470e4b0ed0faba38f60e3303682f2887f12a368b9615618cafa80c83166d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
